This inventor holds 1 USPTO granted patent. Top assignee: Dong-A St Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Kimoon Ryu: Innovator in GCN2 Inhibition
Introduction
Kimoon Ryu is a prominent inventor based in Yongin-si, South Korea. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that act as GCN2 inhibitors. His work is crucial for advancing treatments for diseases related to GCN2 activity.
Latest Patents
One of Kimoon Ryu's notable patents is titled "Compounds as GCN inhibitors, pharmaceutical compositions and uses thereof." This patent presents novel compounds, specifically those of Formula (I), which serve as GCN2 inhibitors. The pharmaceutical compositions derived from these compounds can inhibit GCN2 activity, offering potential therapeutic applications for various diseases.
Career Highlights
Kimoon Ryu is associated with Dong-a ST Co., Ltd., where he continues to innovate in the pharmaceutical sector. His expertise in developing GCN2 inhibitors positions him as a key figure in the industry, contributing to advancements in drug development.
Collaborations
He collaborates with talented colleagues, including Cheonhyoung Park and Tae-hun Kim, to further enhance the research and development efforts at Dong-a ST Co., Ltd.
Conclusion
Kimoon Ryu's work in developing GCN2 inhibitors represents a significant advancement in pharmaceutical innovation. His contributions are vital for the ongoing research and potential treatment of diseases associated with GCN2 activity.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile